1
|
Chaturvedi RN, Pendem K, Patel VP, Sharma M, Malhotra S. Design, synthesis, molecular docking, and in vitro antidiabetic activity of novel PPARγ agonist. MONATSHEFTE FUR CHEMIE 2018. [DOI: 10.1007/s00706-018-2207-x] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
2
|
Xu M, Dong P, Tian X, Wang C, Huo X, Zhang B, Wu L, Deng S, Ma X. Drug interaction study of natural steroids from herbs specifically toward human UDP-glucuronosyltransferase (UGT) 1A4 and their quantitative structure activity relationship (QSAR) analysis for prediction. Pharmacol Res 2016; 110:139-150. [DOI: 10.1016/j.phrs.2016.05.013] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/30/2016] [Revised: 04/26/2016] [Accepted: 05/06/2016] [Indexed: 12/11/2022]
|
3
|
Izumi T, Tsuruta F, Ishizuka T, Nakamura K, Kothuma M, Makoto T. Stereoselectivity in Pharmacokinetics of Rivoglitazone, A Novel Peroxisome Proliferator-Activated Receptor γ Agonist, in Rats and Monkeys: Model-Based Pharmacokinetic Analysis and In Vitro-In Vivo Extrapolation Approach. J Pharm Sci 2013; 102:3174-88. [DOI: 10.1002/jps.23586] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2013] [Revised: 04/12/2013] [Accepted: 04/16/2013] [Indexed: 12/14/2022]
|
4
|
Koffarnus RL, Wargo KA, Phillippe HM. Rivoglitazone: A New Thiazolidinedione for the Treatment of Type 2 Diabetes Mellitus. Ann Pharmacother 2013; 47:877-85. [DOI: 10.1345/aph.1r754] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, and safety of the thiazolidinedione rivoglitazone, a peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist, to determine its potential role in the treatment of type 2 diabetes mellitus. DATA SOURCES: A MEDLINE search (1966-February 2013) was conducted for English-language studies in humans, using the terms rivoglitazone and CS011. Abstracts presented at the American Diabetes Association and European Association for the Study of Diabetes annual meetings from 2007 to 2012 were also evaluated for relevant data. STUDY SELECTION AND DATA EXTRACTION: Articles pertinent to the pharmacology, pharmacokinetics, efficacy, and safety of rivoglitazone were reviewed. DATA SYNTHESIS: Rivoglitazone has been shown, through small clinical studies, to decrease hemoglobin A1c (A1C) by 0.11-1.1% when compared with placebo and may provide greater A1C reduction than pioglitazone. Rivoglitazone reduces hyperglycemia, hyperinsulinemia, and hypertriglyceridemia by acting as an agonist of PPAR-γ. Rivoglitazone is the most potent PPAR-γ agonist; the initial recommended dose is 1 mg daily, with adjustment as needed to a maximum dose of 2 mg daily. Additionally, rivoglitazone has a longer half-life than other PPAR-γ agonists. Similar to those of the other PPAR-γ agonists, rivoglitazone's adverse effects include peripheral edema and weight gain. CONCLUSIONS: Rivoglitazone is the fourth agent in the thiazolidinedione class of antidiabetes drugs. Although rivoglitazone appears to be more potent in its ability to lower A1C levels compared with other thiazolidinediones, further studies of longer duration are needed to fully assess the risks associated with this drug. Until these can be completed, we cannot recommend rivoglitazone over currently approved drugs in this class.
Collapse
Affiliation(s)
- Robin L Koffarnus
- Robin L Koffarnus PharmD BCACP, Assistant Clinical Professor of Pharmacy Practice, Harrison School of Pharmacy, Auburn University, Auburn, AL
| | - Kurt A Wargo
- Kurt A Wargo PharmD BCPS, Associate Clinical Professor of Pharmacy Practice, Harrison School of Pharmacy, Auburn University; Clinical Associate Professor of Internal Medicine, School of Medicine, University of Alabama at Birmingham—Huntsville Campus, Huntsville
| | - Haley M Phillippe
- Haley M Phillippe PharmD BCPS, Associate Clinical Professor of Pharmacy Practice, Harrison School of Pharmacy, Auburn University; Clinical Associate Professor of Family Medicine, School of Medicine, University of Alabama at Birmingham—Huntsville Campus
| |
Collapse
|